Somewhat Negative News Coverage Somewhat Unlikely to Impact Accelerate Diagnostics (AXDX) Stock Price
Media coverage about Accelerate Diagnostics (NASDAQ:AXDX) has trended somewhat negative on Wednesday, Accern Sentiment reports. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Accelerate Diagnostics earned a media sentiment score of -0.01 on Accern’s scale. Accern also assigned news coverage about the medical research company an impact score of 46.3720084830082 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the news articles that may have impacted Accern’s analysis:
- Accelerate Diagnostics (AXDX) Rating Increased to Hold at Zacks Investment Research (americanbankingnews.com)
- Zacks: Accelerate Diagnostics Inc (AXDX) Given $26.50 Average Price Target by Analysts (americanbankingnews.com)
- Stocks To Watch: Accelerate Diagnostics Sees RS Rating Rise To 83 (finance.yahoo.com)
- Analyst Views on This Stock: Accelerate Diagnostics, Inc. (NASDAQ:AXDX) – Clawson News (clawsonnews.com)
- Accelerate Diagnostics to Present at the 36th Annual JP Morgan Healthcare Conference in San Francisco – GlobeNewswire (press release) (globenewswire.com)
Accelerate Diagnostics (NASDAQ AXDX) opened at $27.15 on Wednesday. The firm has a market capitalization of $1,500.00, a P/E ratio of -22.63 and a beta of 2.18. Accelerate Diagnostics has a 1-year low of $16.75 and a 1-year high of $30.45.
Several research firms recently issued reports on AXDX. Zacks Investment Research upgraded Accelerate Diagnostics from a “sell” rating to a “hold” rating in a research report on Monday. BTIG Research cut Accelerate Diagnostics from a “buy” rating to a “neutral” rating in a research report on Wednesday, December 13th. They noted that the move was a valuation call. Two analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the company. Accelerate Diagnostics presently has a consensus rating of “Hold” and an average target price of $33.00.
In other news, Director Jack W. Schuler purchased 5,500 shares of the business’s stock in a transaction on Friday, November 17th. The stock was acquired at an average price of $22.00 per share, for a total transaction of $121,000.00. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, Director Jack W. Schuler purchased 61,300 shares of the business’s stock in a transaction on Friday, October 13th. The shares were purchased at an average price of $19.29 per share, with a total value of $1,182,477.00. The disclosure for this purchase can be found here. Insiders have acquired a total of 930,067 shares of company stock valued at $17,833,992 in the last 90 days. 50.00% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY NOTICE: “Somewhat Negative News Coverage Somewhat Unlikely to Impact Accelerate Diagnostics (AXDX) Stock Price” was posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://www.watchlistnews.com/somewhat-negative-news-coverage-somewhat-unlikely-to-impact-accelerate-diagnostics-axdx-stock-price/1800823.html.
About Accelerate Diagnostics
Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with Analyst Ratings Network's FREE daily email newsletter.